Abiopharma

🔍 McLellan Philip D. (Executive)

Company: QuidelOrtho Corp (QDEL)

Report Date: 2026-04-26

Detailed Transactions and Holdings:

• Acquired 1,946 shares of Common Stock (Direct)
  Date: 2026-04-26 | Code: A | equity_swap_involved: 0 | shares_owned_after: 23,196.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 699 shares of Common Stock at $11.59 per share (Direct)
  Date: 2026-04-26 | Code: F | equity_swap_involved: 0 | shares_owned_after: 22,497.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 1,946 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-26 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F4, F4

Footnotes:

• F1: Reflects release of restricted stock units that were previously reported on a Form 3.
• F2: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units.
• F3: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
• F4: 1,945 shares vested on April 26, 2025; the remaining 1,946 shares vested on April 26, 2026.